By Max Bayer
Kriya Therapeutics has reeled in a whopping $270 million from its series C round, surpassing the $180 million raised in total over the last two years and solidifying ample financing to build out its all-in-one gene therapy business.
read more
By Eric Sagonowsky,Fraiser Kansteiner,Andrea Park,Annalee Armstrong,Kevin Dunleavy
The leaders in this week's Most Influential People in Biopharma category have led companies of all types in this industry—and they're still building today. While they may have scientific and medical expertise, the Fierce team felt their contributions to the business aspects of biopharma made them worth featuring this week.
read more
By Andrea Park
After seven years of bad luck for Avanos Medical’s enteral feeding tube placement system, the FDA has handed down its most serious designation for a recall of the device.
read more
By Kevin Dunleavy
After the departure of CFO Jorge Gomez after just one day on the job, Moderna says that it has agreed with its ousted finance chief to recoup his severance pay if he is found guilty of wrongdoing at his previous stop, Dentsply Sirona.
read more
By Robert King
Providence Health was the latest hospital system to post an earnings loss in the first quarter, announcing a $561 million loss due to a major COVID-19 surge and investment declines.
read more
By James Waldron
Once hailed as the future of immuno-oncology, it looks like TIGITs could now be in trouble. Roche admitted last week to a second phase 3 trial failure for tiragolumab, which was unable to demonstrate the progression-free survival achieved by Tecentriq alone in patients with non-small cell lung cancer.
read more
By Ben Adams
More than two decades ago, Glaxo Wellcome and SmithKline Beecham combined to become GlaxoSmithKline. But as the British Big Pharma looks to slim down its organization with its consumer demerger, its longstanding name is getting the same treatment.
read more
By Andrea Park
Peter Nicholas, who helped found Boston Scientific in 1979 and led the medtech giant as chief executive from then until 1999, died on May 14, just shy of his 81st birthday.
read more
By Fraiser Kansteiner
Emergent will furnish developer Chimerix with $225 million in upfront cash plus upward of $100 million in milestone payments for worldwide exclusive rights to Tembexa. The drug last summer snagged FDA approval as the first antiviral cleared to treat smallpox in patients regardless of their age.
read more
By Conor Hale
After receiving an FDA clearance for its mechanical tendon repair implant late last month, CoNextions Medical reported it has successfully used it to help fix a deep cut in a patient’s little finger.
read more
By Dave Muoio
The lenient sentence was applauded by healthcare workers observing outside of the courthouse as well as professional organizations, which warned that "criminalization of medical errors will not preserve safe patient care environments."
read more
By Nick Paul Taylor
Shionogi is betting $100 million upfront on a new class of antifungal medicine, teaming up with F2G to land the Asian and European rights to a late-phase drug candidate that could help immunocompromised patients failed by existing therapies.
read more
By Conor Hale
Developed by its AI subsidiaries DeepHealth and Quantib, RadNet plans to roll out the tools to its network of 350 outpatient imaging centers.
read more
